Abstract
Fragile X syndrome (FXS) is the most common inherited cause of mental retardation. The behavioral phenotype associated with FXS includes hyperactivity, anxiety, and sometimes problem behaviors for which stimulants, antipsychotics, and SSRI antidepressants are prescribed. Little information, however, is known about the side effects individuals with FXS may experience as a result of taking these medications. Using a nation-wide survey, this study examined the prescription patterns of psychotropic medication use within the FXS population and the prevalence of side effects associated with psychotropic medication use by people diagnosed with FXS. Significant associations were found between the most commonly prescribed medications and side effects for our total sample. These findings give insight to the different dimensions of medication use in people diagnosed with FXS.
Similar content being viewed by others
References
Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of Fragile X mental retardation. Trends in Neurosciences, 27, 370–377. doi:10.1016/j.tins.2004.04.009.
Beckel-Mitchener, A., & Greenough, W. T. (2004). Correlates across the structural, functional, and molecular phenotypes of Fragile X syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 10, 53–59. doi:10.1002/mrdd.20009.
Berry-Kravis, E. (2002). Epilespsy in Fragile X syndrome. Developmental Medicine and Child Neurology, 44, 724–728. doi:10.1017/S0012162201002833.
Berry-Kravis, E., & Huttenlocher, P. R. (1992). Cyclic AMP metabolism in Fragile X syndrome. Annals of Neurology, 31, 22–26. doi:10.1002/ana.410310105.
Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome--present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10, 42–48.
Chiurazzi, P., Neri, G., & Oostra, B. A. (2003). Understanding the biological underpinnings of Fragile X syndrome. Current Opinion in Pediatrics, 15, 559–566. doi:10.1097/00008480-200312000-00003.
Hagerman, R. J. (1997). Fragile X syndrome: molecular and clinical insights and treatment issues. The Western Journal of Medicine, 166, 129–137.
Hagerman, R. J. (2002a). The physical and behavioral phenotype. In R. J. Hagerman, & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment, and research (pp. 3–109, 3rd ed.). Baltimore, MD: The Johns Hopkins University Press.
Hagerman, R. J. (2002b). Medical follow-up and pharmacotherapy. In R. J. Hagerman, & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment, and research (pp. 287–338, 3rd ed.). Baltimore, MD: The Johns Hopkins University Press.
Hagerman, R. J., Fulton, M. J., Leaman, A., Riddle, J., Hagerman, K., & Sobesky, W. (1994). A survey of fluoxetine therapy in Fragile X syndrome. Developmental Brain Dysfunction, 7, 155–164.
Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988). A controlled trial of stimulant medication in children with the fragile X syndrome. American Journal of Medical Genetics, 30, 377–392. doi:10.1002/ajmg.1320300138.
Hilton, D. K., Martin, C. A., Heffron, W. M., Hall, B. D., & Johnson, G. L. (1991). Imipramine treatment of ADHD in a fragile X child. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 831–834. doi:10.1097/00004583-199109000-00021.
Kalachnik, J. E. (1999). Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 348–359. doi:10.1002/(SICI)1098-2779(1999)5:4<348::AID-MRDD13>3.0.CO;2-N.
Kaplowitz, M. D., Hadlock, T. D., & Levine, R. (2004). A comparison of web and mail survey response rates. Public Opinion Quarterly, 68, 94–101.
Sherman, S. (2002). Epidemiology. In R. J. Hagerman, & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment, and research (pp. 136–168, 3rd ed.). Baltimore, MD: The Johns Hopkins University Press.
Tsiouris, J. A., & Brown, W. T. (2004). Neuropsychiatric symptoms of Fragile X syndrome: Pathophysiology and pharmacotherapy. CNS Drugs, 18, 687–703. doi:10.2165/00023210-200418110-00001.
Valdovinos, M. G., & Kennedy, C. H. (2004). Behavior analytic conceptualization of psychotropic medication side effects. The Behavior Analyst, 27, 231–238.
Valdovinos, M. G., & Schroeder, S. R. (2003). The effects of a computerized monitoring system of psychotropic medication use by people with developmental disabilities on staff reported side effects. Journal of Developmental and Physical Disabilities, 15, 299–334. doi:10.1023/A:1026358031999.
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005). Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology, 49, 1053–1066. doi:10.1016/j.neuropharm.2005.06.004.
Acknowledgement
We would like to acknowledge the National Fragile X Foundation for awarding the first author with a Clinical Research Award to support this study and for doing the mailings.
Author information
Authors and Affiliations
Corresponding author
Appendix A
Appendix A
Rights and permissions
About this article
Cite this article
Valdovinos, M.G., Parsa, R.A. & Alexander, M.L. Results of a Nation-Wide Survey Evaluating Psychotropic Medication Use in Fragile X Syndrome. J Dev Phys Disabil 21, 23–37 (2009). https://doi.org/10.1007/s10882-008-9123-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10882-008-9123-7